MupirocinCAS# 12650-69-0 |
- PSI-7977
Catalog No.:BCC1871
CAS No.:1190307-88-0
- Trovafloxacin mesylate
Catalog No.:BCC3931
CAS No.:147059-75-4
- Capecitabine
Catalog No.:BCN2168
CAS No.:154361-50-9
- Viomycin
Catalog No.:BCC3930
CAS No.:32988-50-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 12650-69-0 | SDF | Download SDF |
| PubChem ID | 446596 | Appearance | Powder |
| Formula | C26H44O9 | M.Wt | 500.62 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | BRL-4910A; Pseudomonic acid | ||
| Solubility | DMSO : ≥ 100 mg/mL (199.75 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid | ||
| SMILES | CC(C1C(O1)CC2COC(C(C2O)O)CC(=CC(=O)OCCCCCCCCC(=O)O)C)C(C)O | ||
| Standard InChIKey | MINDHVHHQZYEEK-HBBNESRFSA-N | ||
| Standard InChI | InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Mupirocin Dilution Calculator
Mupirocin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9975 mL | 9.9876 mL | 19.9752 mL | 39.9505 mL | 49.9381 mL |
| 5 mM | 0.3995 mL | 1.9975 mL | 3.995 mL | 7.9901 mL | 9.9876 mL |
| 10 mM | 0.1998 mL | 0.9988 mL | 1.9975 mL | 3.995 mL | 4.9938 mL |
| 50 mM | 0.04 mL | 0.1998 mL | 0.3995 mL | 0.799 mL | 0.9988 mL |
| 100 mM | 0.02 mL | 0.0999 mL | 0.1998 mL | 0.3995 mL | 0.4994 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Mupirocin(BRL-4910A) is an antibiotic of the monoxycarbolic acid class; effective against Gram-positive bacteria, including MRSA.
References:
[1]. Hughes J, et al. Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid. Biochem J. 1978 Oct 15;176(1):305-18.
[2]. Cookson BD. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother. 1998 Jan;41(1):11-8.
- Metasequirin D
Catalog No.:BCN4781
CAS No.:1264694-96-3
- Dihydroeponemycin
Catalog No.:BCC3596
CAS No.:126463-64-7
- (1S,2R)-1-Amino-2-indanol
Catalog No.:BCC8384
CAS No.:126456-43-7
- (R)-CPP
Catalog No.:BCC6581
CAS No.:126453-07-4
- 6-Ethoxygeniposide
Catalog No.:BCN7043
CAS No.:1264496-61-8
- Pyrrolam B
Catalog No.:BCN1986
CAS No.:126424-77-9
- Pyrrolam A
Catalog No.:BCN2040
CAS No.:126424-76-8
- VTP-27999 Hydrochloride
Catalog No.:BCC2050
CAS No.:1264191-73-2
- SR 12813
Catalog No.:BCC7530
CAS No.:126411-39-0
- Colistin Sulfate
Catalog No.:BCC4653
CAS No.:1264-72-8
- Nortropinyl cinnamate
Catalog No.:BCN1891
CAS No.:126394-79-4
- Pinobanksin 3-O-propanoate
Catalog No.:BCN7737
CAS No.:126394-70-5
- CH5183284 (Debio-1347)
Catalog No.:BCC5649
CAS No.:1265229-25-1
- Ciclesonide
Catalog No.:BCC5234
CAS No.:126544-47-6
- 8,14-Epoxyergosta-4,22-diene-3,6-dione
Catalog No.:BCN1591
CAS No.:1265908-20-0
- S1RA hydrochloride
Catalog No.:BCC4190
CAS No.:1265917-14-3
- Cerberidol
Catalog No.:BCN6142
CAS No.:126594-64-7
- Cyclocerberidol
Catalog No.:BCN6143
CAS No.:126594-66-9
- Vallesamine N-oxide
Catalog No.:BCN6144
CAS No.:126594-73-8
- Trilobinine
Catalog No.:BCN7927
CAS No.:126595-92-4
- A 887826
Catalog No.:BCC7898
CAS No.:1266212-81-0
- 16-Epinormacusine B
Catalog No.:BCN4030
CAS No.:126640-98-0
- KT 5823
Catalog No.:BCC7006
CAS No.:126643-37-6
- UTPγS trisodium salt
Catalog No.:BCC7624
CAS No.:1266569-94-1
Zoon Balanitis Revisited: Report of Balanitis Circumscripta Plasmacellularis Resolving With Topical Mupirocin Ointment Monotherapy.[Pubmed:28301626]
J Drugs Dermatol. 2017 Mar 1;16(3):285-287.
INTRODUCTION: Zoon balanitis is an idiopathic benign inflammatory condition of the glans penis and prepuce. A patient with biopsy confirmed diagnosis of Zoon balanitis who was successfully treated with topical Mupirocin ointment monotherapy is described.
METHOD: A search using PubMed database was performed using the following terms: Zoon balanitis (cases, diagnosis, treatment of), balanitis circumscripta plasmacellularis, and Mupirocin. Relevant papers and their reference citations were reviewed and evaluated.
RESULTS: The gold standard of treatment for Zoon balanitis has previously been circumcision. More recently, topical calcineurin inhibitors have been shown to be effective. Our patient had successful resolution of his Zoon balanitis after 3 months of Mupirocin ointment monotherapy.
DISCUSSION: Zoon balanitis is a benign inflammatory dermatosis. Previous successful treatment modalities include circumcision, phototherapy, laser therapy, and topical calcineurin inhibitors. Topical Mupirocin ointment twice daily resulted in resolution of Zoon balanitis in our patient. Additional evaluation of Mupirocin ointment as a therapeutic agent should be considered as a potential first-line therapy in patients with Zoon balanitis.
J Drugs Dermatol. 2017;16(3):285-287.
.Comparison of topical mupirocin and gentamicin in the prevention of peritoneal dialysis-related infections: A systematic review and meta-analysis.[Pubmed:28341139]
Am J Surg. 2018 Jan;215(1):179-185.
BACKGROUND: Topical antibiotics have been shown to reduce exit-site infection and peritonitis. The aim of this study was to compare infection rates between Mupirocin and gentamicin. METHODS: Multiple comprehensive databases were searched systematically to include relevant randomized controlled trials and observational studies. Pooled risk ratios (RRs) and 95% confidence intervals were calculated for the incidences of exit-site infection and peritonitis. RESULTS: Seven studies (Mupirocin group n = 458, gentamicin group n = 448) were analyzed for exit-site infection. The risk of gram-positive exit-site infection was similar between the groups. Gram-negative exit-site infection rate was higher in the Mupirocin group (RR = 2.125, P = 0.037). Six studies were assessed the peritonitis risk. There was no difference in the gram-positive and -negative peritonitis rate. CONCLUSIONS: Topical use of gentamicin is associated with fewer exit-site infections caused by gram-negative organisms. Gentamicin has comparable efficacy to Mupirocin for peritonitis and gram-positive exit-site infection.
Microbiological effect of mupirocin and chlorhexidine for Staphylococcus aureus decolonization in community and nursing home based adults.[Pubmed:28215714]
Diagn Microbiol Infect Dis. 2017 May;88(1):53-57.
OBJECTIVE: To compare the presence of Staphylococcus aureus and pathogenic Gram-negative rods (GNR) in the anterior nares, posterior pharynx and three skin sites in community-based adults and nursing home-based adults before and after treatment with nasal Mupirocin and topical chlorhexidine. METHODS: S. aureus-colonized adults were recruited from the community (n=26) and from nursing homes (n=8). Eligible participants were cultured for S. aureus and GNR during two study visits and then received intranasal Mupirocin and topical chlorhexidine for 5days, with a 2-month follow-up period. RESULTS: After decolonization, we found sustained decreases of S. aureus colonization in nose, throat and skin sites over 4-8weeks in both populations. Intranasal Mupirocin did not increase GNR colonization in nose or throat. Chlorhexidine did not decrease GNR colonization in skin sites. CONCLUSIONS: Decolonization with Mupirocin and chlorhexidine leads to a sustained effect on S. aureus colonization without affecting GNR colonization.
